| MeSH term | MeSH ID | Detail |
|---|---|---|
| Biliary Atresia | D001656 | 4 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Bone Diseases, Developmental | D001848 | 2 associated lipids |
| Bone Diseases, Endocrine | D001849 | 1 associated lipids |
| Bone Diseases, Metabolic | D001851 | 9 associated lipids |
| Bone Neoplasms | D001859 | 5 associated lipids |
| Bone Resorption | D001862 | 7 associated lipids |
| Cachexia | D002100 | 21 associated lipids |
| Calcinosis | D002114 | 5 associated lipids |
| Carcinoid Heart Disease | D002275 | 1 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Boyce BF et al. | Osteoprotegerin, the bone protector, is a surprising target for beta-catenin signaling. | 2005 | Cell Metab. | pmid:16330319 |
| Wang Q et al. | [The molecule mechanism of soybean isoflavaones antagonizing bone loss induced by postmenopausal osteoporosis]. | 2005 | Zhong Yao Cai | pmid:16479929 |
| Guang-Da X et al. | Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients. | 2005 | J. Endocrinol. Invest. | pmid:16483173 |
| Kozaki K | [Current concepts of vascular calcification]. | 2005 | Nihon Ronen Igakkai Zasshi | pmid:16408509 |
| Liu JM et al. | Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. | 2005 | Calcif. Tissue Int. | pmid:15455183 |
| Schoppet M et al. | TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. | 2005 | Biochem. Biophys. Res. Commun. | pmid:16288714 |
| Michael H et al. | Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. | 2005 | J. Bone Miner. Res. | pmid:16294275 |
| Nicholls BM et al. | Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor. | 2005 | J. Bone Miner. Res. | pmid:16294279 |
| Yeung RS | Bones, blood vessels, and the immune system: what's the link? | 2005 | J. Rheumatol. | pmid:16265680 |
| Simonini G et al. | Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement. | 2005 | J. Rheumatol. | pmid:16265708 |
| Kim SM et al. | Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. | 2005 | Clin. Endocrinol. (Oxf) | pmid:16268814 |
| Minenna G et al. | [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report]. | 2005 | Recenti Prog Med | pmid:16229324 |
| Dovio A et al. | Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? | 2005 | J. Endocrinol. Invest. | pmid:16550717 |
| Tarquini R et al. | Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. | 2005 | Biomed. Pharmacother. | pmid:16275499 |
| Zhang B et al. | [Molecular mechanism of bone absorption in osteoclast]. | 2005 | Sheng Wu Yi Xue Gong Cheng Xue Za Zhi | pmid:16422121 |
| Cozzani M et al. | Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption. | 2005 | Prog Orthod | pmid:16276433 |
| Gaudio A et al. | Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role? | 2005 | J. Endocrinol. Invest. | pmid:16277162 |
| Taubman MA et al. | Immune response: the key to bone resorption in periodontal disease. | 2005 | J. Periodontol. | pmid:16277573 |
| Bartold PM et al. | Periodontitis and rheumatoid arthritis: a review. | 2005 | J. Periodontol. | pmid:16277578 |
| Kaji H et al. | Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. | 2005 | Horm. Metab. Res. | pmid:16278780 |
| Ziegler S et al. | Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. | 2005 | Atherosclerosis | pmid:16115489 |
| Gonnelli S et al. | Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. | 2005 | J. Endocrinol. Invest. | pmid:16117195 |
| Zhou Z et al. | Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. | 2005 | Cancer | pmid:16121404 |
| Ashcroft AJ and Carding SR | RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation. | 2005 | Gut | pmid:16099805 |
| Lems WF and Bijlsma JW | [Clinical implications of new insights into the regulation of bone resorption]. | 2005 | Ned Tijdschr Geneeskd | pmid:16104110 |
| Daroszewska A and Ralston SH | Genetics of Paget's disease of bone. | 2005 | Clin. Sci. | pmid:16104845 |
| Rogers A and Eastell R | Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. | 2005 | J. Clin. Endocrinol. Metab. | pmid:16105967 |
| Wise GE et al. | CSF-1 regulation of osteoclastogenesis for tooth eruption. | 2005 | J. Dent. Res. | pmid:16109994 |
| Huang P et al. | [In vitro study of combination rhOPG-Fc and alendronate on inhibition osteoclast]. | 2005 | Zhonghua Wai Ke Za Zhi | pmid:16083587 |
| Kwon OH et al. | The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors. | 2005 | Biochem. Biophys. Res. Commun. | pmid:16083856 |
| Hayton MJ et al. | Involvement of adenosine 5'-triphosphate in ultrasound-induced fracture repair. | 2005 | Ultrasound Med Biol | pmid:16085103 |
| von Knoch F et al. | Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin. | 2005 | J Biomed Mater Res A | pmid:16088891 |
| Kahl KG et al. | Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa. | 2005 | Osteoporos Int | pmid:15300363 |
| Simmons CA et al. | Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. | 2005 | Circ. Res. | pmid:15761200 |
| Rassi CM et al. | Modulation of osteoclastogenesis in porcine bone marrow cultures by quercetin and rutin. | 2005 | Cell Tissue Res. | pmid:15688188 |
| Gallant MA et al. | Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. | 2005 | J. Bone Miner. Res. | pmid:15765187 |
| Silvestrini G et al. | Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. | 2005 | J. Mol. Histol. | pmid:15704000 |
| Zannettino AC et al. | Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. | 2005 | J. Cell. Physiol. | pmid:15799029 |
| Ferrari SL et al. | Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. | 2005 | Endocrinology | pmid:15705780 |
| Tada T et al. | Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. | 2005 | Int. J. Cancer | pmid:15800904 |
| Heymann D et al. | Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools. | 2005 | Drug Discov. Today | pmid:15708742 |
| Mandelin J et al. | Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. | 2005 | J. Rheumatol. | pmid:15801030 |
| Mezquita-Raya P et al. | The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. | 2005 | Osteoporos Int | pmid:15711777 |
| Holmen SL et al. | Essential role of beta-catenin in postnatal bone acquisition. | 2005 | J. Biol. Chem. | pmid:15802266 |
| Skoumal M et al. | Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. | 2005 | Rheumatol. Int. | pmid:15889303 |
| Bernstein CN et al. | Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. | 2005 | Inflamm. Bowel Dis. | pmid:15803021 |
| Inoue H et al. | Prostate cancer mediates osteoclastogenesis through two different pathways. | 2005 | Cancer Lett. | pmid:15890244 |
| Mitani M et al. | Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts. | 2005 | Int. J. Mol. Med. | pmid:15806305 |
| Lynch CC et al. | MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. | 2005 | Cancer Cell | pmid:15894268 |
| Voskaridou E and Terpos E | Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. | 2005 | Eur. J. Haematol. | pmid:15777350 |
| Chang K et al. | Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating factor. | 2005 | J. Orthop. Res. | pmid:15913941 |
| Mossetti G et al. | Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. | 2005 | Bone | pmid:15777635 |
| Depil S et al. | Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. | 2005 | Br. J. Haematol. | pmid:15916694 |
| Janssens K et al. | An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. | 2005 | Bone | pmid:15777670 |
| Fábrega E et al. | Osteoprotegerin and RANKL in alcoholic liver cirrhosis. | 2005 | Liver Int. | pmid:15780054 |
| Fukushima H et al. | IL-1-induced receptor activator of NF-kappa B ligand in human periodontal ligament cells involves ERK-dependent PGE2 production. | 2005 | Bone | pmid:15780952 |
| Regmi A et al. | Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation. | 2005 | Bone | pmid:15780954 |
| Yasuda H | [OPG, anti-rANKL antibody]. | 2005 | Nippon Rinsho | pmid:16164225 |
| Choi BK et al. | Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii. | 2005 | J. Periodontol. | pmid:15898943 |
| Moschen AR et al. | The RANKL/OPG system and bone mineral density in patients with chronic liver disease. | 2005 | J. Hepatol. | pmid:16143421 |
| Carda C et al. | Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint. | 2005 | Tissue Cell | pmid:15899507 |
| Takahashi N et al. | [Osteoprotegerin (OPG)]. | 2005 | Nippon Rinsho | pmid:16149650 |
| Choi JY et al. | Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women. | 2005 | Calcif. Tissue Int. | pmid:16151677 |
| Indridason OS et al. | Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. | 2005 | Osteoporos Int | pmid:15776220 |
| Viereck V et al. | Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. | 2005 | J. Cell. Biochem. | pmid:16152630 |
| Ling LJ et al. | Areca nut extracts modulated expression of alkaline phosphatase and receptor activator of nuclear factor kappaB ligand in osteoblasts. | 2005 | J. Clin. Periodontol. | pmid:15811051 |
| Yamada N et al. | Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor. | 2005 | Cytokine | pmid:15996478 |
| Crisafulli A et al. | Osteoprotegerin and bone mineral density in hemodiafiltration patients. | 2005 | Ren Fail | pmid:16152990 |
| Maïmoun L et al. | Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. | 2005 | Calcif. Tissue Int. | pmid:15812577 |
| Quinn JE et al. | Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. | 2005 | Prostate Cancer Prostatic Dis. | pmid:15999121 |
| Lau YS et al. | Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. | 2005 | Hum. Pathol. | pmid:16153456 |
| Ulrich-Vinther M and Andreassen TT | Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. | 2005 | Calcif. Tissue Int. | pmid:15812581 |
| Ueland T and Bollerslev J | Bone metabolism and growth hormone deficiency. Experimental and clinical aspects. | 2005 | Front Horm Res | pmid:16166760 |
| Ishizuka K et al. | Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. | 2005 | Neurosci. Lett. | pmid:15814197 |
| Frick KK et al. | RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. | 2005 | Am. J. Physiol. Renal Physiol. | pmid:15972386 |
| Ulrich-Vinther M et al. | Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. | 2005 | Bone | pmid:16169783 |
| Cui N et al. | Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. | 2005 | Clin. Cancer Res. | pmid:15814653 |
| Lossdörfer S et al. | PTH(1-34) affects osteoprotegerin production in human PDL cells in vitro. | 2005 | J. Dent. Res. | pmid:15972592 |
| Hjertner Ø et al. | Identification of new targets for therapy of osteolytic bone disease in multiple myeloma. | 2005 | Curr Drug Targets | pmid:16178802 |
| Wang L et al. | Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. | 2005 | Am. J. Physiol. Endocrinol. Metab. | pmid:15585587 |
| Arko B et al. | Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. | 2005 | Maturitas | pmid:15978970 |
| Byrne FR et al. | CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. | 2005 | Gut | pmid:15591508 |
| Otsuka T et al. | Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures. | 2005 | J Dent | pmid:16199283 |
| Neumann E et al. | The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. | 2005 | Arthritis Rheum. | pmid:16200575 |
| Zehnder AF et al. | Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. | 2005 | Laryngoscope | pmid:15630389 |
| Koh JM et al. | Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. | 2005 | J. Endocrinol. | pmid:15930166 |
| Liu D et al. | Chronology and regulation of gene expression of RANKL in the rat dental follicle. | 2005 | Eur. J. Oral Sci. | pmid:16202028 |
| Kees M et al. | Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera. | 2005 | Thromb. Haemost. | pmid:15630493 |
| Bhattacharya A et al. | Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by N-3 fatty acids. | 2005 | J Am Coll Nutr | pmid:15930486 |
| Xie F et al. | Increase in bone mass and bone strength by Sambucus williamsii HANCE in ovariectomized rats. | 2005 | Biol. Pharm. Bull. | pmid:16204939 |
| Mochizuki S et al. | [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis]. | 2005 | Clin Calcium | pmid:15632471 |
| Oh KW et al. | Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. | 2005 | Clin. Endocrinol. (Oxf) | pmid:15638876 |
| Manganelli P et al. | OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? | 2005 | Clin. Rheumatol. | pmid:15583970 |
| Belibasakis GN et al. | The cytolethal distending toxin induces receptor activator of NF-kappaB ligand expression in human gingival fibroblasts and periodontal ligament cells. | 2005 | Infect. Immun. | pmid:15618171 |
| Liu XH et al. | Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. | 2005 | Endocrinology | pmid:15618359 |
| Cao JJ et al. | Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. | 2005 | J. Bone Miner. Res. | pmid:15619667 |
| Liu PY et al. | A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators. | 2005 | J. Clin. Endocrinol. Metab. | pmid:15623811 |
| Marotte H et al. | Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. | 2005 | Arthritis Res. Ther. | pmid:15642135 |
| Katsuyama H et al. | Menaquinone-7 regulates the expressions of osteocalcin, OPG, RANKL and RANK in osteoblastic MC3T3E1 cells. | 2005 | Int. J. Mol. Med. | pmid:15647836 |
| Matayoshi T et al. | Neuropeptide substance P stimulates the formation of osteoclasts via synovial fibroblastic cells. | 2005 | Biochem. Biophys. Res. Commun. | pmid:15649411 |